Bambusa Therapeutics Advances BBT001 Bispecific Antibody to Patient Testing Following Promising Healthy Volunteer Data
核心洞察
Bambusa Therapeutics (搜索) reported highly positive Phase I healthy volunteer results for BBT001, demonstrating favorable safety profile and best-in-class pharmacokinetics with a 33-day half-life.
The first-in-class bispecific antibody targeting IL-4Rα (搜索) and IL-31 (搜索) showed rapid, complete, and sustained receptor binding with unprecedented TARC (搜索) level reduction maintained through Week 8+.
The company has dosed the first moderate-to-severe atopic dermatitis (搜索) patient in its Phase I trial, achieving this milestone within 16 months of company inception.
Bambusa Therapeutics (搜索) has achieved two significant milestones for its lead bispecific antibody BBT001, reporting highly positive healthy volunteer data and initiating patient dosing in its Phase I atopic dermatitis (搜索) trial. The clinical-stage biotechnology company presented compelling safety and pharmacokinetic results at the European Academy of Dermatology and Venereology (EADV) 2025, while simultaneously announcing the dosing of its first moderate-to-severe atopic dermatitis patient.
Exceptional Healthy Volunteer Results Drive Clinical Advancement
The single ascending dose portion of BBT001's Phase I healthy volunteer study demonstrated a favorable safety and tolerability profile across all dose levels with no dose-limiting adverse events. The data revealed a best-in-class pharmacokinetic profile with approximately a 33-day half-life, validating Bambusa's half-life extension technology and supporting flexible dosing regimens for patients.
"These results provide the first clinical evidence of BBT001's potential to become a best-in-disease biologic in atopic dermatitis (搜索)," said Thang Ho, Ph.D., Senior Vice President of Development Sciences at Bambusa Therapeutics (搜索). The study showed rapid, complete, and sustained IL-4Rα (搜索) binding and pSTAT6 (搜索) inhibition observed through Week 8+ following a single dose of BBT001.
Unprecedented TARC Suppression Suggests Superior Efficacy Potential
Perhaps most notably, the study demonstrated an unprecedented, dose-dependent, rapid, deep, and sustained reduction in TARC (搜索) levels after a single dose of BBT001, with potent suppression maintained through Week 8+. Despite low baseline TARC levels in healthy volunteers, researchers observed significant dose-dependent reductions, suggesting synergy between IL-4Rα (搜索) and IL-31 (搜索) inhibition.
Ho emphasized the clinical significance of these findings: "Given the strong correlation between TARC (搜索) reduction and treatment efficacy in atopic dermatitis (搜索), these data give us confidence that BBT001 may deliver faster onset and deeper relief for patients across the Type 2 inflammatory skin disease spectrum."
Rapid Clinical Progression Marks Company Achievement
Bambusa Therapeutics (搜索) has now dosed the first patient with moderate-to-severe atopic dermatitis (搜索) in its Phase I clinical trial, representing a major operational milestone. "Achieving patient dosing within 16 months of company inception underscores our pace of execution and represents a powerful moment for Bambusa Therapeutics and the atopic dermatitis community," said Shanshan Xu, M.D., Ph.D., Founder & Chief Executive Officer of Bambusa Therapeutics.
First-in-Class Dual Targeting Approach
BBT001 represents a first-in-class, multi-targeting, half-life extended bispecific antibody engineered to block both IL-4Rα (搜索) and IL-31 (搜索) signaling. By addressing Type 2 inflammation (搜索) and directly targeting the pathways that drive itch, BBT001 is designed to provide faster and more durable relief for patients with atopic dermatitis (搜索) and other inflammatory skin diseases (搜索).
The BBT001-001 clinical trial is a randomized, placebo-controlled, single- and multiple-ascending-dose study in healthy volunteers and adults with moderate to severe atopic dermatitis (搜索). The trial is evaluating safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary clinical activity. Patient enrollment is ongoing, with additional data expected in 2026.
Xu expressed the company's commitment to advancing treatment options: "With the trial now underway, we feel a deep responsibility to patients to accelerate development, generate proof-of-concept clinical data in patients, challenge and ultimately redefine the standard of care in atopic dermatitis (搜索)."